RLMD · Transaction Dec 12, 2022 · Filed Jan 20, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · RLMD
+0.97% · +$0.0400 · Vol 551.6K
After hours · updated 16:01:39 ET
Relmada Therapeutics Inc
Pharmaceuticals
$4.16
Follow $RLMD
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $RLMD by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredMon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET · RLMD
MethodologyRLMD
Relmada Therapeutics Inc
Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
36/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is RLMD moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Relmada Therapeutics Inc
PHARMACEUTICAL PREPARATIONSListed since
2014
Employees
17
Country
US
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$4.13
Day high
$4.24
Day low
$4.08
Previous close
$4.12
52W high
$7.86
-47.07% from high
52W low
$1.65
40% of range
Market cap
$439.5M
EPS
$-0.9300
Beta
0.96
Shares out
106.7M
Volume
551.6K
0.45× rel vol
Avg volume
1.2M
VWAP
$4.13
Price history computed in-house
1W
-6.31%
1M
-10.15%
3M
-38.55%
1Y
+171.90%
YTD
-13.87%
SMA 50 $4.84 · below
SMA 200 $5.48 · below
52W position 40%
RLMD overview
Related filings and maps
Public disclosures
Congress activity in RLMD
Official filing ↗
Chris JacobsSell
Relmada Therapeutics, Inc. · Transaction Dec 12, 2022 · Filed Jan 20, 2023 · $1,001 to $15,000
RLMD · Transaction Nov 8, 2022 · Filed Dec 12, 2022 · $1,001 to $15,000
Chris JacobsBuy
Relmada Therapeutics, Inc. · Transaction Nov 8, 2022 · Filed Dec 12, 2022 · $1,001 to $15,000
Federal contracts
RLMD contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RLMD in this window.
Lobbying spend
RLMD lobbying filings, year to date.
Registered lobbying filings matched to Relmada Therapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RLMD in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for RLMD.
Options
Sovereign unlock shows live options positioning for RLMD.